AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
taurursodiol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5679 | 14605-22-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Relyvrio contains two active ingredients: sodium phenylbutyrate and taurursodiol, being indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.The mechanism by which relyvrio exerts its therapeutic effects in patients with ALS is unknown.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 13 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 29, 2022 | FDA | AMYLYX |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A05AA05 | ALIMENTARY TRACT AND METABOLISM BILE AND LIVER THERAPY BILE THERAPY Bile acids and derivatives |
| ATC | N07XX19 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D002756 | Cholagogues and Choleretics |
| MeSH PA | D005765 | Gastrointestinal Agents |
Related Drugs by ATC class:
A05AA Bile acids and derivatives 4 drugs
N07XX Other nervous system drugs 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Amyotrophic lateral sclerosis | indication | 86044005 | DOID:332 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3GM/PACKET; 1GM/PACKET | RELYVRIO | AMYLYX | N216660 | Sept. 29, 2022 | DISCN | FOR SUSPENSION | ORAL | 10251896 | Dec. 24, 2033 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS |
| 3GM/PACKET; 1GM/PACKET | RELYVRIO | AMYLYX | N216660 | Sept. 29, 2022 | DISCN | FOR SUSPENSION | ORAL | 10857162 | Dec. 24, 2033 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS |
| 3GM/PACKET; 1GM/PACKET | RELYVRIO | AMYLYX | N216660 | Sept. 29, 2022 | DISCN | FOR SUSPENSION | ORAL | 9872865 | Dec. 24, 2033 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 3GM/PACKET; 1GM/PACKET | RELYVRIO | AMYLYX | N216660 | Sept. 29, 2022 | DISCN | FOR SUSPENSION | ORAL | Sept. 29, 2027 | NEW CHEMICAL ENTITY |
| 3GM/PACKET; 1GM/PACKET | RELYVRIO | AMYLYX | N216660 | Sept. 29, 2022 | DISCN | FOR SUSPENSION | ORAL | Sept. 29, 2029 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bile acid receptor | Nuclear hormone receptor | IC50 | 4.17 | CHEMBL | |||||
| Phospholipase A2 | Enzyme | Kd | 5 | CHEMBL | |||||
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 | Enzyme | IC50 | 4.99 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 5D5 | PDB_CHEM_ID |
| CHEMBL272427 | ChEMBL_ID |
| DB08834 | DRUGBANK_ID |
| 4041745 | VANDF |
| C0075857 | UMLSCUI |
| 11388 | INN_ID |
| 35807-85-3 | SECONDARY_CAS_RN |
| D11836 | KEGG_DRUG |
| 9848818 | PUBCHEM_CID |
| 40914 | MMSL |
| 40943 | MMSL |
| d09918 | MMSL |
| 019092 | NDDF |
| 60EUX8MN5X | UNII |
| 2613950 | RXNORM |
| C031655 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60EUX8MN5X | INXIGHT DRUGS |
Pharmaceutical products:
None